Anti-KDN antibody levels induced after each immunization with different adjuvants were detectedwith indirect enzyme-linked immunosorbent assay.Results: The adjuvant efficiency of Montanide™ ISA 61 VG water in oil adjuvant was 1.4 times higher than in Freund’s adjuvant(p
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Objective: KDN (2-keto-3-deoxy-D-glycero-D-galacto-nononic acid), a member of the sialic acid family, is a hapten-structuredlow-molecular-weight monosaccharide on the cell membrane, which cannot induce immune responses without a carrier protein.Since it is over-expressed on the cancerous cells’ membrane, it is thought to be a great target molecule for anti-cancer treatments.The aim of this study is to obtain high titersof the anti-KDN polyclonal antibody response without using any carrier protein againstthe hapten-structured KDN molecule alternative to Freund’s adjuvants.Methods: Montanide™ ISA 61 VG, a water-in-oil adjuvant; ISA 201 VG, a water-in-oil-in-water emulsion adjuvant; and IMS 1313VG NPR, an aqueous-dispersion-based nanoparticle (50-200 nm) microemulsion adjuvant; and Freund’s adjuvant were used asanti-KDN antibody response stimulators.
📊
Key Findings & Data:FourBALB/c mice were used for each adjuvant group, and immunization was performedat eight different time points.
💡
Conclusion & Impact:Anti-KDN antibody levels induced after each immunization with different adjuvants were detectedwith indirect enzyme-linked immunosorbent assay.Results: The adjuvant efficiency of Montanide™ ISA 61 VG water in oil adjuvant was 1.4 times higher than in Freund’s adjuvant(p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Objective: KDN (2-keto-3-deoxy-D-glycero-D-galacto-nononic acid), a member of the sialic acid family, is a hapten-structuredlow-molecular-weight monosaccharide on the cell membrane, which cannot induce immune responses without a carrier protein.Since it is over-expressed on the cancerous cells’ membrane, it is thought to be a great target molecule for anti-cancer treatments.The aim of this study is to obtain high titersof the anti-KDN polyclonal antibody response without using any carrier protein againstthe hapten-structured KDN molecule alternative to Freund’s adjuvants.Methods: Montanide™ ISA 61 VG, a water-in-oil adjuvant; ISA 201 VG, a water-in-oil-in-water emulsion adjuvant; and IMS 1313VG NPR, an aqueous-dispersion-based nanoparticle (50-200 nm) microemulsion adjuvant; and Freund’s adjuvant were used asanti-KDN antibody response stimulators. FourBALB/c mice were used for each adjuvant group, and immunization was performedat eight different time points. Anti-KDN antibody levels induced after each immunization with different adjuvants were detectedwith indirect enzyme-linked immunosorbent assay.Results: The adjuvant efficiency of Montanide™ ISA 61 VG water in oil adjuvant was 1.4 times higher than in Freund’s adjuvant(p
🔖
Cite This Article
KIMIZ, I., İZ, S. G., GÜRHAN, S. İ. D., METİNER, P. S., KAYALI, Ç. (2022). Polyclonal Antibody Production Against HaptenStructured KDN Molecule by Using Different Adjuvants Alternative to Freund’s Adjuvant. European Journal of Therapeutics, Cilt: 24 - Sayı: 2, 106–111. https://ajindex.com/articles/512332
Inoue S, Lin SL, Chang T, Wu SH, Yao CW, Chu TY, et al. Identification of free deaminated sialic acid (2-Keto-3-deoxy-Dglycero-D-galacto-nononic Acid) in human red blood cells and its elevated expression in fetal cord red blood cells and ovarian cancer cells. J BiolChem 1998; 273: 27199-204. [CrossRef] Gavin AL, Hoebe K, Duong B, Ota T, Martin C, Beutler B, et al. Adjuvant-enhanced antibody responses occur without Toll-like receptor signaling. Science 2006; 314: 1936-8. [CrossRef] Crich D, Navuluri C. Practical synthesis of 2-Keto-3-deoxy-D-glycero-D- galactononulosonic acid (KDN). Org Lett 2011; 13: 6288-91. [CrossRef] Arun Raj GR, Shailaja U, Sagar K, Viswaroopan D, Kumar SN. Swarnaprashana to Swarnamritaprashana: experience inspired modification through ages. Int J Pharm Sci Res 2017; 8: 4546-50.
Inoue S, Kitajima K. KDN (DeaminatedNeuraminic Acid): Dreamful past and exciting future of the newest member of the sialic acid family. Glycoconj J 2006; 23: 277-90. [CrossRef] Go S, Sato C, Yin J, Kannagi R, Kitajima K. Hypoxia-enhanced expression of free deaminoneuraminic acid in human cancer cells. BiochemBiophys Res Commun 2007; 357: 537-42. [CrossRef] Garcia MIG, Carjaval AS, Carmona FG, Ferrer AS. Improved production of 2-keto-3-deoxy-D-glycero-galactononulosonic acid (KDN) using FastPrep-CLEAs. Process Biochem 2014; 49: 90-4. [CrossRef] Lemus R, Karol MH. Conjugation of Haptens. Methods Mol Med 2008; 138: 167-82. [CrossRef] Torres OB, Jalah R, Rice KC, Li F, Antoline JFG, Iyer MR, et al. Characterization and optimization of heroin hapten-BSA conjugates: method development for the synthesis of reproducible hapten-based vaccines. Anal BioalChem 2014; 406: 5927-37. [CrossRef] Rajesh K, Rana KV, Suri CR. Characterization of hapten-protein conjugates: antibody generation and immunoassay development for pesticides monitoring. Bionanoscience 2013; 3: 137-44. [CrossRef] Bröker M, Berti F, Schneider J, Vojtek I. Polysaccharide conjugate vaccine protein carriers as a ‘’neglected valency” - Potential and limitations. Vaccine 2017; 35: 3286-94. [CrossRef] Rajput ZI, Hu SH, Xiao CW, Arijo AG. Adjuvant effects of saponins on animal immune responses. J Zhejiang UnivSci B 2007; 8: 153-61. [CrossRef] Kandil OM, Nassar SA, Nasr SM, Shalaby HAM, Hendawy S, El Moghazy FM. Synergetic effect of Egyptian propolis in immunization of BALB/c mice against bovine cysticercosis. Asian Pac J Trop Biomed 2015; 5: 324-30. [CrossRef] Thompson FM, Porter DW, Okitsu LS, Westerfeld N, Voge